Frazier Life Sciences Management L.P. reduced its stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 28.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,573,719 shares of the biotechnology company's stock after selling 635,470 shares during the quarter. AnaptysBio comprises 0.9% of Frazier Life Sciences Management L.P.'s holdings, making the stock its 25th largest position. Frazier Life Sciences Management L.P. owned 5.17% of AnaptysBio worth $20,836,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently made changes to their positions in the company. Fairmount Funds Management LLC bought a new position in shares of AnaptysBio in the 4th quarter valued at $24,050,000. Boxer Capital Management LLC bought a new stake in shares of AnaptysBio in the 4th quarter valued at $17,212,000. Sanofi acquired a new stake in AnaptysBio during the 4th quarter worth about $10,882,000. Soleus Capital Management L.P. bought a new stake in AnaptysBio in the fourth quarter worth approximately $5,481,000. Finally, Vanguard Group Inc. increased its stake in shares of AnaptysBio by 8.4% in the 4th quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock valued at $24,411,000 after acquiring an additional 143,584 shares in the last quarter.
AnaptysBio Trading Down 1.4%
Shares of ANAB stock traded down $0.30 during mid-day trading on Monday, reaching $20.44. The stock had a trading volume of 357,651 shares, compared to its average volume of 602,268. The firm has a market capitalization of $600.53 million, a PE ratio of -3.36 and a beta of -0.20. The stock's 50-day moving average price is $19.36 and its two-hundred day moving average price is $18.23. AnaptysBio, Inc. has a 52-week low of $12.21 and a 52-week high of $41.31.
AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The biotechnology company reported ($1.28) EPS for the quarter, beating analysts' consensus estimates of ($1.30) by $0.02. The business had revenue of $27.77 million during the quarter, compared to analyst estimates of $15.27 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. On average, equities research analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.
AnaptysBio declared that its Board of Directors has approved a stock buyback program on Monday, March 24th that authorizes the company to repurchase $75.00 million in shares. This repurchase authorization authorizes the biotechnology company to purchase up to 13.1% of its stock through open market purchases. Stock repurchase programs are often a sign that the company's management believes its shares are undervalued.
Analyst Ratings Changes
ANAB has been the subject of a number of analyst reports. HC Wainwright reiterated a "neutral" rating and set a $22.00 price objective on shares of AnaptysBio in a report on Tuesday, March 4th. Wedbush reaffirmed an "outperform" rating and set a $40.00 price target on shares of AnaptysBio in a research report on Thursday, May 1st. Wells Fargo & Company increased their price target on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Wolfe Research began coverage on shares of AnaptysBio in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $25.00 price target for the company. Finally, Guggenheim increased their price objective on AnaptysBio from $52.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Four investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $35.88.
Check Out Our Latest Stock Analysis on ANAB
AnaptysBio Company Profile
(
Free Report)
AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
Read More
Before you consider AnaptysBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AnaptysBio wasn't on the list.
While AnaptysBio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
